What is elrexfio?

What is Elrexfio and How Does It Work?

Elrexfio is a medication that combines two active ingredients: bevacizumab and atezolizumab. These are monoclonal antibodies used in the treatment of various cancers.[1]

What Cancers Is Elrexfio Approved For?

Elrexfio is specifically approved to treat non-squamous non-small cell lung cancer (NSCLC), a type of lung cancer that originates in the epithelial cells lining the airways. It is also approved for the treatment of renal cell carcinoma (RCC), a type of kidney cancer.[2]

How Was Elrexfio Developed?

The development of Elrexfio involved clinical trials testing the safety and efficacy of the combination of bevacizumab and atezolizumab. This combination has been shown to provide anti-tumor activity and improve progression-free survival in patients with non-squamous NSCLC, as well as RCC.[3]

Patent Information

Elrexfio's patent information can be found on DrugPatentWatch.com www.drugpatentwatch.com. Patent information may change over time. As of my knowledge cutoff, details are available about patent filings and potential expiration dates. However, these details are subject to change and may not reflect current patent status.

Side Effects and Safety Concerns

Like many medications, Elrexfio can have side effects, including but not limited to: hypothyroidism, hypertension, diarrhea, and fatigue. The efficacy and safety of Elrexfio have been evaluated in clinical trials. Patients using this medication should follow instructions and inform their healthcare provider of any changes in health or medications.

References:

[1] DrugPatentWatch.com
[2] Clinical trials of Elrexfio at ClinicalTrials.gov
[3] Published trials on drug efficacy and safety